Can the Nexplanon (etonogestrel) subdermal implant cause increased blood pressure in a patient with hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nexplanon and Blood Pressure in Hypertensive Patients

Nexplanon (etonogestrel implant) can be used in women with controlled hypertension (BP <160/100 mmHg) with close monitoring, but women with a history of hypertension-related diseases should be discouraged from using hormonal contraception. 1

Key Distinction: Progestin-Only vs. Combined Hormonal Contraceptives

The critical point is that Nexplanon is a progestin-only contraceptive, which has a fundamentally different blood pressure profile compared to combined estrogen-progestin contraceptives:

Combined Hormonal Contraceptives (NOT Nexplanon):

  • Cause a minor but consistent increase in blood pressure (5-7 mmHg) 2
  • Frank hypertension develops in 0.6-2.8% of users 2
  • The mechanism involves ethinyl estradiol increasing hepatic angiotensinogen synthesis and stimulating the renin-angiotensin-aldosterone system 2
  • Contraindicated in women with controlled hypertension or BP <160/100 mmHg 2
  • Formally contraindicated in uncontrolled hypertension (≥160/100 mmHg) 2

Progestin-Only Methods (Including Nexplanon):

  • No restrictions on use in women with controlled hypertension or BP <160/100 mmHg 2
  • The advantages outweigh theoretical or proven risks even in women with uncontrolled hypertension (≥160/100 mmHg) or history of cardiovascular disease 2
  • Progestin-only methods are the hormonal alternative of choice for hypertensive women 2
  • Data on blood pressure effects are reassuring, though from smaller studies 2

FDA Labeling Guidance for Nexplanon

The FDA label provides specific guidance 1:

  • Women with hypertension-related diseases or renal disease should be discouraged from using hormonal contraception
  • For well-controlled hypertension, Nexplanon use can be considered
  • Close monitoring is mandatory for hypertensive women using Nexplanon
  • Remove Nexplanon if:
    • Sustained hypertension develops during use
    • Significant BP increase does not respond adequately to antihypertensive therapy
  • Annual blood pressure checks are required for all Nexplanon users

Clinical Evidence on Blood Pressure Effects

Research studies show mixed but generally reassuring findings:

  • One Nigerian study found statistically significant increases in systolic BP at 1 year, but no clinically detectable abnormalities 3
  • Another study showed significant reductions in both systolic and diastolic BP at 12 months (though within normal range) 4
  • A 2019 review confirmed that progestin-only contraception appears safe regarding hypertension risk 5
  • A 2026 analysis noted that progestin-only pills and implants have lower or more neutral blood pressure signals compared to combined hormonal contraceptives 6

Practical Management Algorithm

For patients with controlled hypertension (BP <160/100 mmHg):

  1. Nexplanon can be considered as a contraceptive option
  2. Ensure BP is well-controlled on current antihypertensive regimen
  3. Measure baseline BP before insertion
  4. Monitor BP at 3-6 months post-insertion
  5. Continue annual BP monitoring
  6. Remove if sustained hypertension develops or BP becomes unresponsive to therapy

For patients with uncontrolled hypertension (BP ≥160/100 mmHg):

  1. Optimize BP control first
  2. Nexplanon remains an option (advantages outweigh risks per guidelines) 2
  3. Requires more intensive monitoring
  4. Consider alternative non-hormonal methods if BP cannot be controlled

For patients with hypertension-related complications:

  • Renal disease: discouraged per FDA label 1
  • History of cardiovascular disease: advantages still outweigh risks per guidelines 2

Important Caveats

  • The evidence base for progestin-only methods and blood pressure comes from smaller studies compared to combined hormonal contraceptives 2
  • Individual patient response varies—some may experience BP increases while others may see decreases 3, 4
  • Blood pressure measurement before prescribing any hormonal contraception is the only clinical examination recommended by WHO 2
  • The cumulative cardiovascular risk from even small BP elevations over time is clinically significant, particularly in reproductive-aged women 7

Bottom line: Nexplanon is significantly safer than combined hormonal contraceptives for hypertensive patients and can be used with appropriate monitoring, but requires individualized risk assessment and close BP surveillance.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.